indolo[2,3-a]quinolizine | 2254-24-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: indolo[2,3-a]quinolizine
• 英文别名: indolo<2,3-a>quinolizine；Indolo<2,3-a>pyridocolin；indoloquinolizine
• CAS: 2254-24-2
• 化学式: C₁₅H₁₀N₂
• 分子量: 218.258
• InChiKey: CMLQXZNMSSZRCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  indolo[2,3-a]quinolizine 在 platinum(IV) oxide 氢气 作用下， 以 甲醇 为溶剂， 以36%的产率得到1,2,3,4,6,7,12,12b-八氢吲哚并(2,3-a)喹嗪
  参考文献：
  名称：

  A directed metalation route to the zwitterionic indole alkaloids. Syntheses of indolo[2,3-a]quinolizine, flavopereirine, flavocarpine, and dihydroflavopereirine

  摘要：

  DOI：

  10.1016/s0040-4039(00)96702-9
• 作为产物：
  描述：

  2-吡啶甲酸乙酯 在 sodium hydroxide 、 正丁基锂 、 sodium hydride 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 12.0h， 生成 indolo[2,3-a]quinolizine
  参考文献：
  名称：

  A directed metalation route to the zwitterionic indole alkaloids. Syntheses of indolo[2,3-a]quinolizine, flavopereirine, flavocarpine, and dihydroflavopereirine

  摘要：

  DOI：

  10.1016/s0040-4039(00)96702-9

文献信息

• SUBSTITUTED INDOLO [2,3-A] QUINOLIZINES
  申请人：Waldmann Herbert

  公开号：US20120316192A1

  公开（公告）日：2012-12-13

  The present invention relates to novel substituted indolo[2,3-a]quinolizines and stereoisomeric forms thereof and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted indolo[2,3-a]quinolizines together with pharmaceutically acceptable carrier, excipient and/or diluents. Said novel substituted indolo[2,3-a]quinolizines have been identified as useful for the prophylaxis and treatment of cancer by the induction of strong mitotic delays, chromosomal misalignments and mitotic tri- and multipolarization leading to cell cycle stop and apoptosis. Furthermore a synthesis for preparation of the substituted indolo[2,3-a]quinolizines is disclosed in the present invention.

  本发明涉及新型的取代吲哚[2,3-a]喹诺里嗪及其立体异构体和/或这些化合物的药用可接受盐，以及包含至少一种这些取代吲哚[2,3-a]喹诺里嗪的药物组合物，以及药用可接受的载体、辅料和/或稀释剂。所述新型取代吲哚[2,3-a]喹诺里嗪已被确认为通过诱导强烈的有丝分裂延迟、染色体错位和有丝分裂三极和/或多极化导致细胞周期停止和凋亡，用于癌症的预防和治疗的有用物质。此外，本发明还公开了取代吲哚[2,3-a]喹诺里嗪的合成方法。
• Syntheses of camalexin, indolopyridocoline and flavopereirine
  作者：Alois Fürstner、Andreas Ernst

  DOI：10.1016/0040-4020(94)00987-6

  日期：1995.1

  synthetic route to the phytoalexin camalexin 7 and a convergent approach to the alkaloids indolopyridocoline 8, 6,7-dihydroflavopereirine 15 and flavopereirine 9 are presented. Starting from well accessible precursors, these total syntheses highlight the preparative potential of a new method for indole synthesis based on the formation of the C2C3 bond by low-valent titanium induced reductive coupling of oxo-amides

  到植物抗毒素camalexin的短的合成路线7和会聚的方法来生物碱indolopyridocoline 8，6,7- dihydroflavopereirine 15和flavopereirine 9被呈现。从容易获得的前体开始，这些总的合成突出了基于低价钛诱导的氧代酰胺的还原形成C2 lowC3键的吲哚合成新方法的制备潜力。
• Total synthesis of new indolo[2,3-a]quinolizine alkaloids sempervirine type, potential pharmaceuticals
  作者：Teodozja M. Lipińska

  DOI：10.1016/j.tet.2006.03.085

  日期：2006.6

  the AB–DE synthons, has been obtained. The final stages: desulfuration, and formation of the C-ring via the Gribble method have led to the expected zwitterionic alkaloids. Model syntheses of the indolopyridocoline and its methoxy analogue from 2-acetylpyridine have been performed for investigation of the microwave-induced Fischer synthesis of sensitive indoles and for obtaining compounds for comparative

  从5-乙酰基-3-甲硫基-1分五个步骤详细阐述了两个系列的新五环杂环[ g ]吲哚并[2,3- a ]喹诺嗪生物碱（改性的sempervirine具有广泛的活性）的全合成。，2,4-三嗪（得自简单的无环材料）。在两个关键步骤中：电子逆需求Diors–Alder反应与环烯胺反应的前体，以及随后的3-乙酰基-1-甲基硫代环烷基的费歇尔吲哚化反应[ c已经获得了AB-DE合成子]吡啶。最后阶段：脱硫和通过Gribble方法形成C环已导致预期的两性离子生物碱。已经进行了吲哚吡咯啉及其从2-乙酰基吡啶的甲氧基类似物的模型合成，以研究敏感的吲哚的微波诱导费歇尔合成，并获得用于光谱数据比较研究的化合物。
• Indole derivatives and anti-ulcer compositions thereof
  申请人：Nisshin Flour Milling Co., Ltd.

  公开号：US05252580A1

  公开（公告）日：1993-10-12

  Disclosed are indole derivatives of formula (I) ##STR1## wherein Y represents H, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy or halogen; Z represents --CH.sub.2 N(R.sub.5)--; R represents H or --CH.sub.2 CH.sub.2 X where X represents pyridyl, aralkyloxy or substituted amino of NR.sub.6 R.sub.7 where R.sub.6 represents H, C.sub.1 -C.sub.6 alkyl, aralkyl, C.sub.1 -C.sub.6 alkoxycarbonyl, aralkyloxycarbonyl or halogenated C.sub.1 -C.sub.6 alkoxycarbonyl and R.sub.7 represents H, C.sub.1 -C.sub.6 alkyl or aralkyl, or together with R.sub.2 may form a ring of --(CH.sub.2).sub.n -- (n is 1-4) or ##STR2## R.sub.1 represents H, C.sub.1 -C.sub.6 alkyl, aralkyl or arylsulfonyl; R.sub.2 represents C.sub.1 -C.sub.6 alkyl, hydroxy, C.sub.1 -C.sub.6 alkoxy or aralkyloxy; R.sub.3 represents H, C.sub.1 -C.sub.6 alkyl, aralkyl or halogenated C.sub.1 -C.sub.6 alkyl; R.sub.4 and R.sub.5 may be the same or different and each represents H, C.sub.1 -C.sub.6 alkyl or aralkyl or both may together form a ring of --(CH.sub.2).sub.m -- (m is 3 or 4); or pharmaceutically acceptable acid addition salts thereof. They are useful as an antiulcer agent.

  本发明涉及公式（I）的吲哚衍生物##STR1##其中Y代表H，C.sub.1 -C.sub.6烷基，C.sub.1 -C.sub.6烷氧基或卤素；Z代表--CH.sub.2 N(R.sub.5)--；R代表H或--CH.sub.2 CH.sub.2 X，其中X代表吡啶基，芳基氧基或NR.sub.6 R.sub.7的取代氨基，其中R.sub.6代表H，C.sub.1 -C.sub.6烷基，芳基烷基，C.sub.1 -C.sub.6烷氧羰基，芳基氧羰基或卤代C.sub.1 -C.sub.6烷氧羰基，R.sub.7代表H，C.sub.1 -C.sub.6烷基或芳基烷基，或与R.sub.2一起形成--(CH.sub.2).sub.n --（n为1-4）的环或##STR2##R.sub.1代表H，C.sub.1 -C.sub.6烷基，芳基烷基或芳基磺酰基；R.sub.2代表C.sub.1 -C.sub.6烷基，羟基，C.sub.1 -C.sub.6烷氧基或芳基氧基；R.sub.3代表H，C.sub.1 -C.sub.6烷基，芳基烷基或卤代C.sub.1 -C.sub.6烷基；R.sub.4和R.sub.5可以相同也可以不同，每个代表H，C.sub.1 -C.sub.6烷基或芳基烷基，或两者一起形成--(CH.sub.2).sub.m --（m为3或4）的环；或其药学上可接受的酸盐。它们可用作抗溃疡剂。
• Substituted indolo [2,3-a] quinolizines in the treatment of cancer
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP2532664A1

  公开（公告）日：2012-12-12

  The present invention relates to novel substituted indolo [2,3-a] quinolizines of the general formula (I) and stereoisomeric forms thereof and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted indolo [2,3-a] quinolizines together with pharmaceutically acceptable carrier, excipient and/or diluents. Said novel substituted indolo [2,3-a] quinolizines have been identified as useful for the prophylaxis and treatment of cancer by the induction of strong mitotic delays, chromosomal misalignments and mitotic tri- and multipolarization leading to cell cycle stop and apoptosis. Furthermore a synthesis for preparation of the substituted indolo [2,3-a] quinolizines is disclosed in the present invention.

  本发明涉及新颖的取代吲哚[2,3-a]喹啉化合物，其一般式为(I)，以及其立体异构体和/或这些化合物的药学上可接受的盐，以及含有至少一种这些取代吲哚[2,3-a]喹啉的药物组合物，其中还包括药学上可接受的载体、赋形剂和/或稀释剂。所述的新颖取代吲哚[2,3-a]喹啉已被确定为用于预防和治疗癌症的有用药物，通过诱导强烈的有丝分裂延迟、染色体错位和有丝分裂三价和多价化导致细胞周期停滞和凋亡。此外，本发明还公开了一种用于制备取代吲哚[2,3-a]喹啉的合成方法。